PROCEPT BioRobotics Corporation
PRCTHealthcareNASDAQMedical Devices · Last scanned Sep 8, 2026
Scan Results
Daily timeframePROCEPT BioRobotics Corporation, a surgical robotics company, develops transformative solutions in urology in the United States and internationally. The $1.30B market capitalization puts PRCT squarely in small-cap range for its industry. It develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery focusing on treating benign prostatic hyperplasia.
Market Cap
$1.30B
Beta
0.90
P/E (TTM)
—
P/E (Fwd)
-19.74
EPS (TTM)
$-1.95
EPS (Fwd)
$-1.15
ROE
-30.2%
ROA
-14.8%
Cash
$227.9M
Total Debt
$77.5M
Free CF
-$49.0M
52W Change
-41.5%
Annual Financials
Cash vs Debt
Where PRCT stands vs its 150-day and 200-day moving averages
As of the September 3, 2026 close, PRCT finished 8.80% below its 150-day moving average ($24.09) and 15.76% below its 200-day moving average ($26.08). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is PRCT overbought or oversold?
At the September 3, 2026 close, PRCT's RSI(14) was 50.1, in neutral territory (between 30 and 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The balance sheet looks solid with $227.9M in cash comfortably exceeding the $77.5M debt load. A net cash position generally provides financial flexibility during uncertain economic periods. Free cash flow is running at -$49.0M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. ROE of -30.2% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Revenue has grown from $75.0M (2022) to $308.1M (2025), reflecting a 311% increase over the period.
With cash comfortably exceeding debt, PRCT has financial flexibility that may help navigate uncertain periods. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. No single metric tells the full story. Reviewing PRCT's risk profile alongside its fundamentals and technical indicators provides a more complete picture.